• Patrick A Flume, James D Chalmers, and Kenneth N Olivier.
• Department of Medicine and Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA. Electronic address: flumepa@musc.edu.
• Lancet. 2018 Sep 8; 392 (10150): 880-890.

AbstractBronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common feature of a heterogeneous set of conditions and clinical presentations. No approved therapies exist for the condition other than for bronchiectasis caused by cystic fibrosis. The heterogeneity of bronchiectasis is a major challenge in clinical practice and the main reason for difficulty in achieving endpoints in clinical trials. Recent observations of the past 2 years have improved the understanding of physicians regarding bronchiectasis, and have indicated that it might be more effective to classify patients in a different way. Patients could be categorised according to a heterogeneous group of endotypes (defined by a distinct functional or pathobiological mechanism) or by clinical phenotypes (defined by relevant and common features of the disease). In doing so, more specific therapies needed to effectively treat patients might finally be developed. Here, we describe some of the recent advances in endotyping, genetics, and disease heterogeneity of bronchiectasis including observations related to the microbiome.Copyright © 2018 Elsevier Ltd. All rights reserved.

17 keywords...

hide…